HKPDNasdaqWholesale-Drugs, Proprietaries & Druggists' SundriesFiscal year ends March 31
Cellyan Biotechnology Co., Ltd
Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Aug 7, 2026
$0.11+0.00 (+1.81%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Cellyan Biotechnology Co., Ltd revenue by segment
By business segment
By product or service
| Revenue | FY2026 | FY2025 | FY2024 | FY2023 | % of revenue | YoY |
|---|---|---|---|---|---|---|
| Supply chain services [Member] | $7.56M | $12.48M | $10.15M | $8.05M | 56.3% | -39.5% |
| Procurement and distribution [Member] | $5.87M | $7.51M | $6.22M | $4.48M | 43.7% | -21.8% |
| Consignment sales and other revenue [Member] | $4.18K | $321.04K | $324.71K | $23.04K | 0.0% | -98.7% |
By region
From the segment and revenue-disaggregation notes of Cellyan Biotechnology's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.